Literature DB >> 2234057

Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways.

L Teyton1, D O'Sullivan, P W Dickson, V Lotteau, A Sette, P Fink, P A Peterson.   

Abstract

Class I MHC molecules acquire peptides from endogenously synthesized proteins, whereas class II antigens present peptides derived from extracellular compartment molecules. This dichotomy is due to the fact that the invariant chain associates with class II molecules in the endoplasmic reticulum, preventing binding of endogenous peptides. The mutually exclusive binding of peptide and invariant chain to class II molecules suggests that the invariant chain might play a part in autoimmune disease.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2234057     DOI： 10.1038/348039a0

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


  68 in total

1.  Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains.

Authors:  K Frauwirth; N Shastri
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

2.  Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments.

Authors:  G Moldenhauer; C Henne; J Karhausen; P Möller
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

3.  Distinct binding sites on HLA-DR for invariant chain and staphylococcal enterotoxins.

Authors:  D R Karp; R N Jenkins; E O Long
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

Review 4.  Dynamic nature and function of epidermal Langerhans cells in vivo and in vitro: a review, with emphasis on human Langerhans cells.

Authors:  M B Teunissen
Journal:  Histochem J       Date:  1992-10

5.  Invariant chain can function as a chaperone protein for class II major histocompatibility complex molecules.

Authors:  M S Anderson; J Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

6.  Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules.

Authors:  P A Roche; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

7.  RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors.

Authors:  T E Willnow; A Rohlmann; J Horton; H Otani; J R Braun; R E Hammer; J Herz
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

8.  Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.

Authors:  S Baskar; S Ostrand-Rosenberg; N Nabavi; L M Nadler; G J Freeman; L H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

9.  The Ii41 isoform of invariant chain mediates both positive and negative selection events in T-cell receptor transgenic mice.

Authors:  R J Wright; E K Bikoff; B Stockinger
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

10.  Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.

Authors:  Marvin M van Luijn; Martine E D Chamuleau; James A Thompson; Suzanne Ostrand-Rosenberg; Theresia M Westers; Yuri Souwer; Gert J Ossenkoppele; S Marieke van Ham; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.